Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/36452
Title: Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in de Novo Kidney Transplant Recipients
Authors: Tedesco-Silva Junior, Hélio [UNIFESP]
Kho, M. M. L.
Hartmann, A.
Vitko, S.
Russ, G.
Rostaing, L.
Budde, K.
Campistol, J. M.
Eris, J.
Krishnan, I.
Gopalakrishnan, U.
Klupp, J.
Universidade Federal de São Paulo (UNIFESP)
Erasmus Univ
Univ Oslo
Inst Clin & Expt Med
Royal Adelaide Hosp
CHU Rangueil
Charite
Univ Barcelona
Royal Prince Alfred Hosp
Novartis Pharma AG
Novartis Healthcare Pvt Ltd
Keywords: Cyclosporine
efficacy
everolimus
kidney transplantation
sotrastaurin
Issue Date: 1-Jul-2013
Publisher: Wiley-Blackwell
Citation: American Journal of Transplantation. Hoboken: Wiley-Blackwell, v. 13, n. 7, p. 1757-1768, 2013.
Abstract: Sotrastaurin, a novel selective protein-kinase-C inhibitor, inhibits early T cell activation via a calcineurin-independent pathway. Efficacy and safety of sotrastaurin in a calcineurin inhibitorfree regimen were evaluated in this two-stage Phase II study of de novo kidney transplant recipients. Stage 1 randomized 131 patients (2:1) to sotrastaurin 300mg or cyclosporine A (CsA). Stage 2 randomized 180 patients (1:1:1) to sotrastaurin 300 or 200mg or CsA. All patients received basiliximab, everolimus (EVR) and prednisone. Primary endpoint was composite efficacy failure rate of treated biopsy-proven acute rejection, graft loss, death or lost to follow-up. Main safety assessment was estimated glomerular filtration rate (eGFR) by MDRD-4 at Month 12. Composite efficacy failure rates at 12 months were higher in sotrastaurin arms (Stage 1: 16.5% and 10.9% for sotrastaurin 300mg and CsA; Stage 2: 27.2%, 34.5% and 19.4% for sotrastaurin 200mg, 300mg and CsA). eGFR was significantly better in sotrastaurin groups versus CsA at most time points, except at 12 months. Gastrointestinal and cardiac adverse events were more frequent with sotrastaurin. Higher treatment discontinuation, deaths and graft losses occurred with sotrastaurin 300mg. Sotrastaurin combined with EVR showed higher efficacy failure rates and some improvement in renal allograft function compared to a CsA-based therapy.
URI: http://repositorio.unifesp.br/handle/11600/36452
ISSN: 1600-6135
Other Identifiers: http://dx.doi.org/10.1111/ajt.12255
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.